The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Introduction: Medroxyprogesterone acetate (MPA), the major progestin used for oral contraception and hormone replacement therapy, has been implicated in increased breast cancer risk. Is this risk due to its progestational or androgenic properties? To address this, we assessed the transcriptional effects of MPA as compared with those of progesterone and dihydrotestosterone (DHT) in human breast cancer cells. Method: A new progesterone receptor-negative, androgen receptor-positive human breast cancer cell line, designated Y-AR, was engineered and characterized. Transcription assays using a synthetic promoter/reporter construct, as well as endogenous gene expression profiling comparing progesterone, MPA and DHT, were performed in cells either lacking or containing progesterone receptor and/or androgen receptor. Results: In progesterone receptor-positive cells, MPA was found to be an effective progestin through both progesterone receptor isoforms in transient transcription assays. Interestingly, DHT signaled through progesterone receptor type B. Expression profiling of endogenous progesterone receptor-regulated genes comparing progesterone and MPA suggested that although MPA may be a somewhat more potent progestin than progesterone, it is qualitatively similar to progesterone. To address effects of MPA through androgen receptor, expression profiling was performed comparing progesterone, MPA and DHT using Y-AR cells. These studies showed extensive gene regulatory overlap between DHT and MPA through androgen receptor and none with progesterone. Interestingly, there was no difference between pharmacological MPA and physiological MPA, suggesting that high-dose therapeutic MPA may be superfluous. Conclusion: Our comparison of the gene regulatory profiles of MPA and progesterone suggests that, for physiologic hormone replacement therapy, the actions of MPA do not mimic those of endogenous progesterone alone. Clinically, the complex pharmacology of MPA not only influences its side-effect profile; but it is also possible that the increased breast cancer risk and/or the therapeutic efficacy of MPA in cancer treatment is in part mediated by androgen receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Transcriptional activation and nuclear targeting signals of the human androgen receptor.
Simental, J. A., Sar, M., Lane, M. V., French, F. S., & Wilson, E. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52466-2 · Cited by 631
Strähle, U., Klock, G., & Schütz, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.7871 · Cited by 355
Poulin, R., Baker, D., & Labrie, F. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01805942 · Cited by 172 · cited 1×
“MPA also has known glucocorticoid [40,41] and androgenic [40,42,43] activities in breast cancer cells.”
BackgroundBirrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., & Tilley, W. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1572 · Cited by 87 · cited 1×
“In addition to its use in contraception and HRT, MPA is also commonly used to treat endometrial cancer and as a second line agent to treat breast cancer [37]; for these indications its serum levels are approximately 0.”
BackgroundPoulin, R., Baker, D., Poirier, D., & Labrie, F. (1989) · Breast Cancer Research and Treatment · doi:10.1007/bf01806528 · Cited by 83 · cited 1×
“MPA also has known glucocorticoid [40,41] and androgenic [40,42,43] activities in breast cancer cells.”
BackgroundPoulin, R., Baker, D., Poirier, D., & Labrie, F. (1991) · Breast Cancer Research and Treatment · doi:10.1007/bf01806369 · Cited by 73
Cited by
Stanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
“Interestingly, the same authors detected some cell-specific differences in breast cancer cell lines between the maximal responses and potencies of MPA compared with R5020 on a synthetic PRE-luciferase construct,most likelydue todifferent relativeconcentrations of proteins other than the PR, although this was not estab…”
BackgroundCloke, B., Huhtinen, K., Fusi, L., Kajihara, T., Yliheikkilä, M., Ho, K.-K., Teklenburg, G., Lavery, S., Jones, M. C., Trew, G., et al. (2008) · Endocrinology · doi:10.1210/en.2008-0356 · Cited by 159
Strowitzki, T., Faustmann, T., Gerlinger, C., Schumacher, U., Ahlers, C., & Seitz, C. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s77202 · Cited by 120
Metadata
- Authors
- Ghatge, R. P., Jacobsen, B. M., Schittone, S. A., & Horwitz, K. B.
- Venue
- Breast Cancer Research
- Published
- 2005-11-02
- Volume
- 7
- Issue
- 6
- Pages
- R1036-50
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1867169935
- Cited by
- 65
- References
- 12
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.